2025-05-01 2026-04-30 2026-04-30 false 10736975 Antiverse Ltd 72110Research and experimental development on biotechnology iso4217:GBP xbrli:pure 107369752025-05-01 107369752026-04-30 107369752025-05-01 2026-04-30 10736975bus:SmallEntities2025-05-01 2026-04-30 10736975bus:AuditExempt-NoAccountantsReport2025-05-01 2026-04-30 10736975bus:FullAccounts2025-05-01 2026-04-30 10736975core:WithinOneYear2026-04-30 10736975core:AfterOneYear2026-04-30 10736975core:WithinOneYear2025-05-01 2026-04-30 10736975core:AfterOneYear2025-05-01 2026-04-30 10736975core:CurrentFinancialInstruments2026-04-30 10736975core:Non-currentFinancialInstruments2026-04-30 10736975core:CurrentFinancialInstruments2025-05-01 2026-04-30 10736975core:Non-currentFinancialInstruments2025-05-01 2026-04-30 10736975core:LandBuildings2025-05-01 2026-04-30 10736975core:FurnitureFittings2025-05-01 2026-04-30 10736975core:OfficeEquipment2025-05-01 2026-04-30 10736975core:Vehicles2025-05-01 2026-04-30 10736975core:PlantMachinery2025-05-01 2026-04-30 10736975core:OtherPropertyPlantEquipment2025-05-01 2026-04-30 10736975core:LandBuildings2026-04-30 10736975core:PlantMachinery2026-04-30 10736975core:Vehicles2026-04-30 10736975core:FurnitureFittings2026-04-30 10736975core:OfficeEquipment2026-04-30 10736975core:OtherPropertyPlantEquipment2026-04-30 10736975core:Right-of-useAssets2025-05-01 2026-04-30 10736975core:Right-of-useAssets2026-04-30 10736975core:Goodwill2025-05-01 2026-04-30 10736975core:PatentsTrademarksLicencesConcessionsSimilar2025-05-01 2026-04-30 10736975core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-05-01 2026-04-30 10736975core:OtherResidualIntangibleAssets2025-05-01 2026-04-30 10736975core:Goodwill2026-04-30 10736975core:DevelopmentCostsCapitalisedDevelopmentExpenditure2026-04-30 10736975core:PatentsTrademarksLicencesConcessionsSimilar2026-04-30 10736975core:OtherResidualIntangibleAssets2026-04-30 10736975dpl:CostSales2025-05-01 2026-04-30 10736975dpl:AdministrativeExpenses2025-05-01 2026-04-30 10736975dpl:DistributionCosts2025-05-01 2026-04-3010736975core:ShareCapital2026-04-30 10736975core:SharePremium2026-04-30 10736975core:RevaluationReserve2026-04-30 10736975core:OtherReservesSubtotal2026-04-30 10736975core:ShareCapitalPreferenceShares2026-04-30 10736975core:CapitalRedemptionReserve2026-04-30 10736975core:OtherCapitalReserve2026-04-30 10736975core:RetainedEarningsAccumulatedLosses2026-04-3010736975core:ShareCapital2025-05-01 2026-04-30 10736975core:SharePremium2025-05-01 2026-04-30 10736975core:RevaluationReserve2025-05-01 2026-04-30 10736975core:OtherReservesSubtotal2025-05-01 2026-04-30 10736975core:RetainedEarningsAccumulatedLosses2025-05-01 2026-04-301073697512025-05-01 2026-04-30 1073697522025-05-01 2026-04-3010736975core:ShareCapital12025-05-01 2026-04-30 10736975core:ShareCapital22025-05-01 2026-04-3010736975core:SharePremium12025-05-01 2026-04-30 10736975core:SharePremium22025-05-01 2026-04-3010736975core:RevaluationReserve12025-05-01 2026-04-30 10736975core:RevaluationReserve22025-05-01 2026-04-3010736975core:RetainedEarningsAccumulatedLosses12025-05-01 2026-04-30 10736975core:RetainedEarningsAccumulatedLosses22025-05-01 2026-04-301073697512025-05-01 2026-04-3010736975core:Non-currentFinancialInstrumentscore:CostValuation2025-05-01 10736975core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2026-04-30 10736975core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2026-04-3010736975core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2026-04-30 10736975core:Non-currentFinancialInstrumentscore:TransfersIntoOrOutInvestmentsIncreaseDecreaseInInvestments2026-04-30 10736975core:Non-currentFinancialInstrumentscore:CostValuation2026-04-3010736975core:Non-currentFinancialInstrumentscore:ProvisionsForImpairmentInvestments2025-05-01 10736975core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2026-04-30 10736975core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2026-04-30 10736975core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2026-04-30 10736975core:Non-currentFinancialInstrumentscore:FurtherSpecificIncreaseDecreaseInProvisionsForImpairmentInvestments1ComponentCorrespondingTotal2026-04-30 10736975core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2026-04-30 10736975core:Non-currentFinancialInstrumentscore:ProvisionsForImpairmentInvestments2026-04-3010736975core:Non-currentFinancialInstruments2026-04-30 10736975core:Non-currentFinancialInstruments2025-04-30107369752024-05-01 107369752025-04-30 107369752024-05-01 2025-04-30 10736975core:WithinOneYear2025-04-30 10736975core:AfterOneYear2025-04-30 10736975core:CurrentFinancialInstruments2025-04-30 10736975core:Non-currentFinancialInstruments2025-04-30 10736975core:LandBuildings2025-04-30 10736975core:PlantMachinery2025-04-30 10736975core:Vehicles2025-04-30 10736975core:FurnitureFittings2025-04-30 10736975core:OfficeEquipment2025-04-30 10736975core:OtherPropertyPlantEquipment2025-04-30 10736975core:Right-of-useAssets2025-04-30 10736975core:Goodwill2025-04-30 10736975core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-04-30 10736975core:PatentsTrademarksLicencesConcessionsSimilar2025-04-30 10736975core:OtherResidualIntangibleAssets2025-04-30 10736975dpl:AdministrativeExpenses2024-05-01 2025-04-3010736975core:ShareCapital2025-04-30 10736975core:SharePremium2025-04-30 10736975core:RevaluationReserve2025-04-30 10736975core:OtherReservesSubtotal2025-04-30 10736975core:ShareCapitalPreferenceShares2025-04-30 10736975core:CapitalRedemptionReserve2025-04-30 10736975core:OtherCapitalReserve2025-04-30 10736975core:RetainedEarningsAccumulatedLosses2025-04-3010736975core:RetainedEarningsAccumulatedLosses2024-05-01 10736975core:ShareCapital2024-05-01 10736975core:SharePremium2024-05-01 10736975core:RevaluationReserve2024-05-01 10736975core:ShareCapital2024-05-01 2025-04-30 10736975core:SharePremium2024-05-01 2025-04-30 10736975core:RevaluationReserve2024-05-01 2025-04-30 10736975core:OtherReservesSubtotal2024-05-01 2025-04-30 10736975core:RetainedEarningsAccumulatedLosses2024-05-01 2025-04-301073697512024-05-01 2025-04-30 1073697522024-05-01 2025-04-3010736975core:ShareCapital12024-05-01 2025-04-30 10736975core:ShareCapital22024-05-01 2025-04-3010736975core:SharePremium12024-05-01 2025-04-30 10736975core:SharePremium22024-05-01 2025-04-3010736975core:RevaluationReserve12024-05-01 2025-04-30 10736975core:RevaluationReserve22024-05-01 2025-04-3010736975core:RetainedEarningsAccumulatedLosses12024-05-01 2025-04-30 10736975core:RetainedEarningsAccumulatedLosses22024-05-01 2025-04-3010736975bus:Director12025-05-01 2026-04-3010736975bus:Director22025-05-01 2026-04-3010736975bus:Director32025-05-01 2026-04-3010736975bus:Director42025-05-01 2026-04-3010736975bus:Director52025-05-01 2026-04-3010736975bus:Director62025-05-01 2026-04-3010736975bus:Director72025-05-01 2026-04-3010736975bus:Director82025-05-01 2026-04-3010736975bus:Director92025-05-01 2026-04-3010736975bus:Director102025-05-01 2026-04-3010736975bus:PrivateLimitedCompanyLtd2025-05-01 2026-04-30
Antiverse Ltd
Unaudited Financial Statements
for the year ended 30 April 2026
Company registration number 10736975
(England and Wales)

Company Information

For the year ended 30 April 2026
Directors Kubias, Karel
Kunsch, Charles
Fates, Richard Matthiessen
Pack, Peter, Dr.
Tunaboylu, Murat
Gebeily, Jean
Kreiner, Thane
Sikyta, Michal
Papenfuss, Kerstin, Dr
Holland, Benjamin Thomas Tristram

Registered office Sbarc, Spark 5th Floor
Maindy Rd
Cardiff
CF24 4HQ

Registered number 10736975

Accountant Countex Finance Ltd
Future Space
UWE North Gate
Filton Road
Bristol
Gloucestershire
BS34 8RB

Statement of Financial Position

As at 30 April 2026
Notes
2026
2025
£
£
£
£
Fixed assets
Tangible assets
4
93,596
160,562
Investments
347
8
93,943
160,570
Current assets
Debtors
5
776,500
1,047,912
Cash at bank and in hand
1,619,444
1,035,802
2,395,944
2,083,714
Creditors
Amounts falling due within one year
6
(789,663)
(900,707)
(789,663)
(900,707)
Net current assets (liabilities)
1,606,281
1,183,007
Total assets less current liabilities
1,700,224
1,343,577
Creditors
Amounts falling due after one year
(27,372)
(73,961)
(27,372)
(73,961)
Net assets (liabilities)
1,672,852
1,269,616
Capital and reserves
Called up share capital
23
19
Share premium account
10,767,859
6,940,606
Other reserves
429,675
175,724
Profit and loss account
(9,524,705)
(5,846,733)
Total equity
1,672,852
1,269,616

The company is a private company limited by shares and registered in England and Wales. It was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
The financial statements have been prepared in accordance with the special provisions applicable to companies subject to the small companies regime.
The directors have chosen to not file a copy of the company's profit and loss account under section 444 (5A) of the Companies Act 2006.

The financial statements were approved and authorised for issue by the Board of Directors on 26 October 2026 and are signed on its behalf by:

Tunaboylu, Murat
Tunaboylu, Murat
Director
Holland, Benjamin Thomas Tristram
Holland, Benjamin Thomas Tristram
Director

Company registration number 10736975

Notes to the Financial Statements

For the year ended 30 April 2026

1. Statutory information

The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The financial statements are presented in sterling and this is the functional currency of the company.

2. Accounting policies

2.1. Basis of preparation

The financial statements have been prepared in accordance with FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.

The financial statements have been prepared under the historical cost convention in accordance with the Companies Act 2006.

2.2. Going concern

After reviewing the company's forecasts and projections, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. The company therefore continues to adopt the going concern basis of accounting in preparing its financial statements.

2.3. Turnover

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.


Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transaction can be measured reliably.


Revenue from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.

2.4. Current taxation

Current tax is recognised in profit or loss, except for taxes related to revaluations of land and buildings which are recognised in other comprehensive income.


Current tax represents the amount of tax payable (receivable) in respect of taxable profit (loss) for the current, or past, reporting periods. Current tax is measured at the amount expected to be paid (recovered) using the tax rates and laws which have been enacted, or substantively enacted, by the balance sheet date. Where payments to HM Revenue and Customs exceed liabilities owed, an asset is recognised to the extent of the amount of tax recoverable.

2.5. Tangible fixed assets and depreciation

All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

Rate
Method
%
Office and computer equipment
25
Straight-line
Other tangible assets
67
Straight-line

2.6. Investments

Investments in subsidiaries, associates, and joint ventures are measured at cost less any accumulated impairment losses.

2.7. Financial instruments

Election and recognition

The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.


Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

3. Employees

The average number of employees during the year was 19 (2025: 15).

4. Tangible fixed assets

Other tangible assets
Total
£
£
Cost
At 1 May 2025
301,684
301,684
Additions
79,659
79,659
At 30 April 2026
381,343
381,343
Depreciation and impairment
At 1 May 2025
141,122
141,122
Charge for the period
146,625
146,625
At 30 April 2026
287,747
287,747
Net book value
At 30 April 2026
93,596
93,596
At 30 April 2025
160,562
160,562

Other tangible assets includes lab equipment and computer equipment.

5. Debtors

2026
2025
£
£
Trade debtors
154,335
30,015
Other debtors
610,063
985,729
Prepayments and accrued income
12,102
32,168
Total due within one year
776,500
1,047,912
Total due after one year
-
-
Total
776,500
1,047,912

6. Creditors due within one year

2026
2025
£
£
Trade creditors
368,599
366,516
Other creditors
7,915
423,684
Lease liabilities
46,614
46,614
Taxation and social security
325,121
49,253
Accruals and deferred income
41,414
14,640
Total
789,663
900,707